Cardio Diagnostics Holdings, Inc. Expected to Earn Q2 2023 Earnings of ($0.21) Per Share (NASDAQ:CDIO)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Rating) – Research analysts at Northland Capmk issued their Q2 2023 EPS estimates for Cardio Diagnostics in a report issued on Monday, May 22nd. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings of ($0.21) per share for the quarter. Northland Capmk also issued estimates for Cardio Diagnostics’ Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.75) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.55) EPS.

Separately, Northland Securities started coverage on shares of Cardio Diagnostics in a research report on Monday. They set an “outperform” rating for the company.

Cardio Diagnostics Stock Performance

NASDAQ CDIO opened at $1.32 on Wednesday. The company has a 50-day simple moving average of $2.74 and a two-hundred day simple moving average of $2.23. Cardio Diagnostics has a 12-month low of $0.80 and a 12-month high of $10.25.

Institutional Trading of Cardio Diagnostics

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE purchased a new stake in Cardio Diagnostics during the first quarter valued at about $59,000. Susquehanna International Group LLP purchased a new stake in shares of Cardio Diagnostics during the fourth quarter worth about $26,000. State Street Corp purchased a new stake in shares of Cardio Diagnostics during the first quarter worth about $163,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Cardio Diagnostics during the first quarter worth about $290,000. 77.29% of the stock is currently owned by hedge funds and other institutional investors.

About Cardio Diagnostics

(Get Rating)

Cardio Diagnostics Holdings, Inc, a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.